Liver cancer treatment that ‘baths’ the organ in chemotherapy is effective in 90% of patients

Consultant interventional radiologist Dr Brian Stedman said his team performed 300 procedures on 100 patients who developed liver cancer after it spread from their eye.

In a study published in the journal Melanoma Research, the team found that liver cancers were controlled in 88.9% of patients who received chemosaturation therapy, with 62% surviving for one year and 30% for more than two years. .

A spokesperson for PLANETS, the charity that funded the research, said the average survival time for those studied was 15 months and in some cases treatment almost completely eradicated the cancer.

Dr Stedman, co-founder of PLANETS, said: “When we first tested this treatment on two patients in 2012, I said the development would be a watershed moment in cancer care and it’s really turned out to be given these results.

“This treatment allows us to cut an organ from the body for 60 minutes, soak it in a heavy dose of medicine and then filter the blood almost completely clean before returning it, and its arrival was much needed.”

He added that the study showed that the method is safe and that patients feel back to normal in just a few days while avoiding some side effects of traditional chemotherapy.

Neil Pearce, study co-author, consultant hepatobiliary surgeon and co-founder of PLANETS, said: “While we currently only have evidence for this treatment in liver cancer that has spread from of the eye, these findings may now open the door for future studies with other hard-to-treat cancers affecting the liver, and we are exploring potential new research trials.

“There has also been limited research and case reports on other cancers – including bowel, breast, pancreas and neuroendocrine – from international centers that suggest potential benefit but should be further evaluated. formally in large clinical trials.

“But these findings show that there is real potential for this treatment to expand to more common cancers, which is very exciting.”

Scientists at the Cancer Research Institute released promising results on Monday that could help future patients fight lung cancer and potentially other forms of the disease.

An artificial intelligence technique analyzes tumor samples and is able to suggest drug combinations that may be useful for a particular patient. The technology’s suggestions can be produced in less than two days, and in lab tests, 128 of the 252 drug combinations showed some degree of synergy.

“The test has the potential to guide doctors in making judgments about which treatments are most likely to benefit cancer patients,” said Udai Banerji, professor of molecular cancer pharmacology at ICR and lead on the study.

“This is an important step forward from our current goal of using genetic mutations to predict response.”

Comments are closed.